RxDoctor Payments Data

John Pilch, MD

Neurology · Greenville, SCNPI 1487648044

Payments from drug & device makers

$7,351in general payments, 2019–2025

Across 579 payments — averaging $12.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$3K
  • AbbVie$2K
  • Zyla Life Sciences, Inc.$329
  • MDD US Operations, LLC$239
  • Supernus Pharmaceuticals, Inc.$239
  • Pfizer$199
  • plus $885 from 14 others

What the payments were for

  • Food & beverage$7,21898%
  • Education$1332%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,351 in reported general payments places this provider in the 70th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina

Medicare billing

Part B allowed, 2024
$184,387
Medicare patients
541
Services billed
7,403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TecfideraDimethyl Fumarate15$138,307
UbrelvyUbrogepant31$40,020
Emgality SyringeGalcanezumab-Gnlm13$21,564
QuliptaAtogepant14$20,864
Lacosamide33$11,918
Emgality PenGalcanezumab-Gnlm13$11,669
Memantine Hcl139$5,926
Carbidopa-LevodopaCarbidopa/Levodopa107$5,447
Dimethyl Fumarate20$4,783
Baclofen190$4,632
Gabapentin206$4,424
Levetiracetam143$3,886
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone14$3,306
Donepezil Hcl200$3,279
Duloxetine Hcl117$3,099

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$2,261$60,88445 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 270 neurology providers in South Carolina.

Other neurology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →